Olema Pharmaceuticals Inc. has advanced its program targeting KAT6, an epigenetic target dysregulated in breast and other cancers, with the selection of a development candidate, OP-3136. The orally bioavailable, potent KAT6A/B-selective inhibitor has been developed by Olema in collaboration with Aurigene Oncology Ltd.
Hinova Pharmaceuticals Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to an estrogen receptor (ER)-targeting moiety through a linker.
Researchers from China Pharmaceutical University have reported the discovery and preclinical evaluation of novel bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer.
Sana Biotechnology Inc. has obtained FDA clearance of its IND application to conduct a study of SC-262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed chimeric antigen receptor (CAR) T therapy.
Researchers from Third Military Medical University of the Chinese PLA have published data from a study that aimed to investigate the biological functions and molecular mechanisms of tandem C2 domains, nuclear (TC2N) in the development and progression of breast cancer.
It is largely known that the expression of programmed cell death 1 ligand 1 (PD-L1) contributes to immune evasion by cancer cells, thus avoiding the cytotoxic effect exerted by T cells. Therefore, it is important to understand the mechanisms regulating PD-L1 levels.
Researchers at Monash University in Melbourne have discovered that transcription factors Ikaros and Aiolos work by binding to AP-1 transcriptional complexes and driving their transcription, which regulates thousands of genes in the human body.
RSS
